<DOC>
	<DOC>NCT00112034</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients with continued disease activity on AVONEX monotherapy.</brief_summary>
	<brief_title>AVONEX速 Combination Trial - "ACT"</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age 18 to 55, inclusive Diagnosis of MS A relapsingremitting course Expanded Disability Status Scale (EDSS) score 0.05.5 inclusive at Baseline Currently receiving AVONEX速 therapy Treated with AVONEX速 for at least 6 consecutive months prior Breakthrough disease (clinical relapse or gadoliniumenhancing MRI lesion) during the prior 12 months, at least 6 months after initiating AVONEX therapy. History of cirrhosis, chronic hepatitis, or currently active hepatitis History of poorlycontrolled hypertension, diabetes mellitus, or peptic ulcer disease History of aseptic bone necrosis, osteoporosis, or osteoporosisrelated bone fracture History of steroidinduced psychosis. History of or abnormal laboratory results indicating significant illness History of severe allergic or anaphylactic reactions or known drug hypersensitivity or intolerance to MTX, IVMP, or AVONEX速. History of allergy to albumin History of any episode of suicidal ideation or severe depression within 3 months of the Screening Visit. History of seizure within 3 months prior to the Screening Visit. Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS MS relapse with onset within 60 days prior to the Baseline Visit Any metallic or electronic material or device in the body, or condition that precludes the subject from undergoing MRI with gadolinium administration A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days of the Screening Visit Abnormal blood tests, performed at the Screening Visit, which exceed any of the limits defined by the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting</keyword>
	<keyword>AVONEX</keyword>
	<keyword>Combination</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>IV Methylprednisolone</keyword>
	<keyword>IVMP</keyword>
	<keyword>ACT</keyword>
	<keyword>MTX</keyword>
</DOC>